LONGEVA.

P021 (P21): limits of adverse-event evidence

Kazim and colleagues gave dietary P021 to female transgenic and control mice for 12 months. The inspected abstract describes an Alzheimer’s disease model, rather than a human adverse-event trial. [1]

The abstract gives no clinical adverse-reaction frequencies. These findings cannot establish human or batch-specific risks. This P021 is CNTF-derived; evidence about the p21/CDKN1A protein does not describe the same compound. [1]

What the studies reported

EffectModel or participantsHow often or as describedSource
Clinical adverse-reaction frequenciesFemale transgenic and control mice, dietary P021 for 12 months (Alzheimer’s disease model)The abstract describes a disease model rather than a human adverse-event trial; it gives no clinical adverse-reaction frequencies[1]

References

  1. Kazim SF et al. (2014). Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease https://doi.org/10.1016/j.nbd.2014.07.001.